At a glance
- Originator POLA
- Class Antiallergics; Antiasthmatics; Small molecules
- Mechanism of Action Nitric oxide donors; Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 11 Jun 2001 No-Development-Reported for Allergic asthma in Japan (Unknown route)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Allergic asthma in Japan (Unknown route)